IN VITRO AND IN VIVO EFFECTS OF P-MAPA IMMUNOMODULATOR ON SCHISTOSOMIASIS

Acta Trop. 2021 Mar 28:105909. doi: 10.1016/j.actatropica.2021.105909. Online ahead of print.

ABSTRACT

Schistosomiasis is an infectious disease caused by helminth parasites of the genus Schistosoma; it is transmitted in over 78 countries. The main strategy for schistosomiasis control is treatment of infected people with praziquantel (PZQ). As PZQ-resistant strains have emerged, new anti-schistosomal agents have become necessary. We evaluated the in vitro and in vivo effect of P-MAPA, an aggregated polymer of protein magnesium ammonium phospholinoleate-palmitoleate anhydride with immunomodulatory properties; it is produced by Aspergillus oryzae fermentation. In vitro, P-MAPA (5, 50, and 100 µg/mL) damaged the Schistosoma mansoni tegument, causing thorn losses and tuber destruction in male worms and peeling and erosion in females after 24-h incubation. In vivo, P-MAPA (5 and 100 mg/kg, alone and combined with PZQ – 50 mg/kg) reduced the number of eggs by up to 69.20% in in the liver and 88.08% in the intestine. Furthermore, granulomas were reduced up to 83.13%, and there was an increase in the number of dead eggs and a reduction of serum aspartate aminotransferase levels. These data suggest that P-MAPA activity can help improve schistosomiasis treatment and patients’ quality of life.

PMID:33789153 | DOI:10.1016/j.actatropica.2021.105909

Source: Industry